Citations

Clear

6273 citation(s) found for "To, Andrew".

Biomarkers Associated with Progression of Diabetic Kidney Disease: Do They Hold the Same Meaning for Blacks and Women?
Hickson, LaTonya J. , Jaffe, Allan S. , Rule, Andrew D. , Rule, Andrew D , Hickson, LaTonya J , Balls‐Berry, Joyce E. , Jaffe, Allan S.

Mayo Clinic

Journal of the American Society of Nephrology | April 20, 2018 | Volume: 29 | Issue: 6 | Pages: 1781-1781

10.1681/asn.2017121249 | PMID 29678999 Get It

Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)
Khoury, Paneez , Akuthota, Praveen , Ackerman, Steven J. , Arron, Joseph R. , Bochner, Bruce S. , Kahn, Jean‐Emmanuel , Fulkerson, Patricia C., Gleich, Gerald J. , Gopal-Srivastava, Rashmi, Jacobsen, Elizabeth A. , Leiferman, Kristen M, Francesca, Levi-Schaffer, Mathur, Sameer K. , Minnicozzi, Michael, Roufosse, Florence , Sable, Kathleen, Simon, Dagmar , Simon, Hans‐Uwe , Spencer, Lisa A. , Steinfeld, Jonathan , Wardlaw, Andrew J. , Weller, Peter F. , Bochner, Bruce S , Simon, Hans Uwe , Jacobsen, Elizabeth A , Collins, Margaret H. , Francesca, Levi-Schaffer, Prussin, Calman , Rothenberg, Marc E. , Wechsler, Michael E , Klion, Amy D.

Mayo Clinic

Journal of Leukocyte Biology | April 19, 2018 | Volume: 104 | Issue: 1 | Pages: 69-83

10.1002/jlb.5mr0118-028r | PMID 29672914 Get It

AbstractEosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.Review on eosinophil biology and eosinophil-related disorders (2012–2017) with a focus on continued unmet needs in eosinophil-associated diseases.
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Maurer, Matthew J. , Ghesquières, Hervé , Link, Brian K. , Jais, Jean‐Philippe, Thompson, Carrie A. , Haïoun, Corinne , Allmer, Cristine, Johnston, Patrick B. , Delarue, Richard, Micallef, Ivana N. , Peyrade, Frédéric, Inwards, David J. , Ketterer, Nicolas , Farooq, Umar , Fitoussi, Olivier , Macon, William R. , Molina, Thierry Jo , Syrbu, Sergei , Weiner, George J. , Ansell, Stephen M. , Salles, Gilles , Tilly, Hervé , Nowakowski, Grzegorz S. , Molina, Thierry J, Salles, Gilles A, Maurer, Matthew , Link, Brian K , Farooq, Umar , Salles, Gilles A , Weiner, George , Jaïs, Jean‐Philippe , Habermann, Thomas M. , Feldman, Andrew L. , Slager, Susan L. , Cerhan, James R. , Witzig, Thomas E. , Syrbu, Sergei

Mayo Clinic

Journal of Clinical Oncology | April 19, 2018 | Volume: 36 | Issue: 16 | Pages: 1603-1610

10.1200/jco.2017.76.5198 | PMID 29672223 Get It

Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States. Validation of results was performed in an independent, clinical trial-based cohort from Europe. Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource (MER; N = 986) or the Lymphoma Study Association (LYSA) LNH-2003 clinical trials program (N = 1,444). All patients received anthracycline-based immunochemotherapy at initial diagnosis. Associations of DTI with clinical factors and outcome were examined. Outcome was assessed using event-free survival at 24 months from diagnosis (EFS24). Results Median (range) DTI was 15 days (0 to 155 days in the MER and 23 days (0 to 215 days) in LYSA. Shorter DTI was strongly associated with adverse clinical factors, including elevated lactate dehydrogenase levels, poor performance status, B symptoms, and higher International Prognostic Index in both cohorts (all P < .001). Longer DTI was associated with improved EFS24 in both the MER (per-week odds ratio, 0.80; 95% CI, 0.74 to .0.87) and LYSA (per-week odds ratio, 0.90; 95% CI, 0.86 to 0.94); association with EFS24 remained significant after adjustment for International Prognostic Index. Conclusion DTI is strongly associated with prognostic clinical factors and outcome in newly diagnosed DLBCL. DTI should be reported in all clinical trials of newly diagnosed DLBCL and future trials should take steps to avoid selection bias due to treatment delay.
Neuropsychological and Behavioral Outcomes after Exposure of Young Children to Procedures Requiring General Anesthesia
Zaccariello, Michael J. , Katusic, Slavica K., Schroeder, Darrell R. , Hanson, Andrew C. , Schulte, Phillip J. , Buenvenida, Shonie L., Gleich, Stephen J. , Wilder, Robert T., Hu, Danqing , Voigt, Robert G. , Paule, Merle G. , Chelonis, John J. , Flick, Randall P., Schroeder, Darrell , Warner, David O. , Šprung, Juraj

Mayo Clinic

Anesthesiology | April 19, 2018 | Volume: 129 | Issue: 1 | Pages: 89-105

10.1097/aln.0000000000002232 | PMID 29672337 Get It

Abstract Background Few studies of how exposure of children to anesthesia may affect neurodevelopment employ comprehensive neuropsychological assessments. This study tested the hypothesis that exposure to multiple, but not single, procedures requiring anesthesia before age 3 yr is associated with adverse neurodevelopmental outcomes. Methods Unexposed, singly exposed, and multiply exposed children born in Olmsted County, Minnesota, from 1994 to 2007 were sampled using a propensity-guided approach and underwent neuropsychological testing at ages 8 to 12 or 15 to 20 yr. The primary outcome was the Full-Scale intelligence quotient standard score of the Wechsler Abbreviated Scale of Intelligence. Secondary outcomes included individual domains from a comprehensive neuropsychological assessment and parent reports. Results In total, 997 children completed testing (411, 380, and 206 unexposed, singly exposed, and multiply exposed, respectively). The primary outcome of intelligence quotient did not differ significantly according to exposure status; multiply exposed and singly exposed children scoring 1.3 points (95% CI, −3.8 to 1.2; P = 0.32) and 0.5 points (95% CI, −2.8 to 1.9; P = 0.70) lower than unexposed children, respectively. For secondary outcomes, processing speed and fine motor abilities were decreased in multiply but not singly exposed children; other domains did not differ. The parents of multiply exposed children reported increased problems related to executive function, behavior, and reading. Conclusions Anesthesia exposure before age 3 yr was not associated with deficits in the primary outcome of general intelligence. Although secondary outcomes must be interpreted cautiously, they suggest the hypothesis that multiple, but not single, exposures are associated with a pattern of changes in specific neuropsychological domains that is associated with behavioral and learning difficulties.
Allogeneic Stem Cell Transplantation Alone is Unlikely to Provide the HIV-1 Cure
Cummins, Nathan W. , Badley, Andrew D.

Mayo Clinic

Future Virology | April 19, 2018 | Volume: 13 | Issue: 5 | Pages: 307-308

10.2217/fvl-2018-0005 Get It

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
Bachy, Emmanuel , Habermann, Thomas M., Gelas‐Dore, Bénédicte, Estell, Jane, Neste, Éric Van Den, Bouabdallah, Réda, Gyan, Emmanuel , Bargay, Joan , Slager, Susan L., Silva, María Gomes da , Fitoussi, Olivier , Intragumtornchai, Tanin , Ansell, Stephen M., Lamy, T. , Dartigues, Peggy , Link, Brian K. , Seymour, John F., Salles, Gilles , Link, Brian K , Gyan, Emmanuel , Salles, Gilles A , Maurer, Matthew J. , Habermann, Thomas M. , Maucort‐Boulch, Delphine , Feldman, Andrew L. , Delmer, Alain , Slager, Susan L. , Belada, David , Maisonneuve, Hervé , Ansell, Stephen M. , Cerhan, James R. , Bachy, Emmanuel

Mayo Clinic

Blood | April 17, 2018 | Volume: 132 | Issue: 1 | Pages: 49-58

10.1182/blood-2017-11-816405 | PMID 29666118 Get It

Key Points In FL, no prognostic index has been built based solely on a large cohort of patients treated with initial immunochemotherapy. The PRIMA-PI is a simplified index based on β2m and bone marrow involvement for patients treated with immunochemotherapy.
Anatomic total shoulder arthroplasty with posterior capsular plication versus reverse shoulder arthroplasty in patients with biconcave glenoids: A matched cohort study
Wanderman, Nathan , Assenmacher, Andrew T. , Sperling, John W. , Cofield, Robert H. , Alentorn-Geli, Eduard, Wanderman, Nathan R, Assenmacher, Andrew T , Sanchez-Sotelo, Joaquin, Alentorn‐Geli, Eduard , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Orthopaedic Surgery | April 17, 2018 | Volume: 26 | Issue: 2 | Pages: No page available

10.1177/2309499018768570 | PMID 29661111 Get It

Purpose: To compare the outcomes of total shoulder arthroplasty (TSA) with posterior capsule plication (PCP) and reverse shoulder arthroplasty (RSA) in patients with primary osteoarthritis, posterior subluxation, and bone loss (Walch B2). Patients and methods: All shoulders undergoing anatomic TSA with PCP were retrospectively identified (group 1, G1) and compared to shoulders undergoing RSA (group 2, G2) for Walch B2 osteoarthritis. There were 15 patients in G1 (mean (SD) age and follow-up of 70.5 (7.5) years and 42.8 (18.4) months, respectively) and 16 patients in G2 (mean (SD) age and follow-up of 72.6 (5.4) years and 35.1 (14.2) months, respectively). Results: Both groups had substantial improvements in pain and function. In G1, results were excellent in 80% and satisfactory in 20%, compared to 81% and 6% in G2, respectively ( p = 0.2). The mean (SD) American Shoulder and Elbow Surgeons score was 91.2 (6.7) and 80.3 (14.3) in G1 and G2, respectively ( p = 0.08). The mean Simple Shoulder Test score was 10.6 in G1 and 8.5 in G2 ( p = 0.01). There were no reoperations in either group, but G1 had seven postoperative complications. Conclusions: The outcomes of TSA with PCP are comparable to RSA in patients with osteoarthritis and biconcave glenoids. However, TSA leads to more complications while RSA leads to lower functional outcomes.
Glial fibrillary acid protein
McKeon, Andrew , Benarroch, Eduardo E. , McKeon, Andrew

Mayo Clinic

Neurology | April 13, 2018 | Volume: 90 | Issue: 20 | Pages: 925-930

10.1212/wnl.0000000000005534 | PMID 29653988 Get It

Glycine Amidinotransferase (GATM), Renal Fanconi Syndrome, and Kidney Failure
Reichold, Markus, Klootwijk, Enriko, Reinders, Jörg , Milani, Mario , Broeker, Carsten, Laing, Chris, Wiesner, J., Devi, Sulochana, Zhou, Weibin , Schmitt, Roland , Tegtmeier, Ines , Sterner, Christina, Doellerer, Hannes, Renner, Kathrin , Oefner, Peter J. , Dettmer, Katja , Simbuerger, Johann M.B., Stanescu, Horia , Dumitriu, Simona, Patel, Vaksha , Mozere, Monika, Tekman, Mehmet , Jaureguiberry, Graciana, Issler, Naomi, Kesselheim, Anne, Walsh, Stephen B. , Gale, Daniel P. , Howie, Alexander J. , Martins, Joana Raquel , Hall, Andrew M. , Kasgharian, Michael, O’Brien, Kevin , Jain, Mahim , Hammers, Alexander , Charles‐Edwards, Geoff , Choe, Chi‐un , Isbrandt, Dirk , Cebrian-Serrano, Alberto , Sandford, Richard , Konecki, David, Povey, Sue, Lichter‐Konecki, Uta , Gahl, William A. , Warth, Richard , Kleta, Robert , Gale, Daniel P , Davies, Ben , Bockenhauer, Detlef , Warth, Richard , Kleta, Robert , Otto, Edgar A. , Witzgall, Ralph , Iancu, Daniela , Ferreira, Carlos R , Atwal, Paldeep S , Pugh, Christopher William , Unwin, Robert John

Mayo Clinic

Journal of the American Society of Nephrology | April 13, 2018 | Volume: 29 | Issue: 7 | Pages: 1849-1858

10.1681/asn.2017111179 | PMID 29654216 Get It

Background For many patients with kidney failure, the cause and underlying defect remain unknown. Here, we describe a novel mechanism of a genetic order characterized by renal Fanconi syndrome and kidney failure. Methods We clinically and genetically characterized members of five families with autosomal dominant renal Fanconi syndrome and kidney failure. We performed genome-wide linkage analysis, sequencing, and expression studies in kidney biopsy specimens and renal cells along with knockout mouse studies and evaluations of mitochondrial morphology and function. Structural studies examined the effects of recognized mutations. Results The renal disease in these patients resulted from monoallelic mutations in the gene encoding glycine amidinotransferase (GATM), a renal proximal tubular enzyme in the creatine biosynthetic pathway that is otherwise associated with a recessive disorder of creatine deficiency. In silico analysis showed that the particular GATM mutations, identified in 28 members of the five families, create an additional interaction interface within the GATM protein and likely cause the linear aggregation of GATM observed in patient biopsy specimens and cultured proximal tubule cells. GATM aggregates-containing mitochondria were elongated and associated with increased ROS production, activation of the NLRP3 inflammasome, enhanced expression of the profibrotic cytokine IL-18, and increased cell death. Conclusions In this novel genetic disorder, fully penetrant heterozygous missense mutations in GATM trigger intramitochondrial fibrillary deposition of GATM and lead to elongated and abnormal mitochondria. We speculate that this renal proximal tubular mitochondrial pathology initiates a response from the inflammasome, with subsequent development of kidney fibrosis.
HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome
Natesampillai, Sekar, Cummins, Nathan W. , Nie, Zilin , Sampath, Rahul , Baker, Jason V. , Henry, Keith , Pinzone, Marilia Rita , O’Doherty, Una , Bren, Gary D., Katzmann, David J. , Badley, Andrew D. , Polley, Eric C. , Cummins, Nathan W , Badley, Andrew D , O’Doherty, Una

Mayo Clinic

Journal of Virology | April 10, 2018 | Volume: 92 | Issue: 13 | Pages: No page available

10.1128/jvi.00037-18 | PMID 29643240 Get It

ABSTRACT HIV protease is known to cause cell death, which is dependent upon cleavage of procaspase 8. HIV protease cleavage of procaspase 8 generates Casp8p41, which directly binds Bak with nanomolar affinity, causing Bak activation and consequent cell death. Casp8p41 can also bind Bcl2 with nanomolar affinity, in which case cell death is averted. Central memory CD4 T cells express high levels of Bcl2, possibly explaining why those cells do not die when they reactivate HIV. Here, we determine that the Casp8p41-Bcl2 complex is polyubiquitinated and degraded by the proteasome. Ixazomib, a proteasome inhibitor in clinical use, blocks this pathway, increasing the abundance of Casp8p41 and causing more cells to die in a Casp8p41-dependent manner. IMPORTANCE The Casp8p41 pathway of cell death is unique to HIV-infected cells yet is blocked by Bcl2. Once bound by Bcl2, Casp8p41 is polyubiquitinated and degraded by the proteasome. Proteasome inhibition blocks degradation of Casp8p41, increasing Casp8p41 levels and causing more HIV-infected cells to die.